A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Beijing Cancer Hospital, Beijing